- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 3 - The Far-Reaching Burden of Rare Diseases
In addition to the substantial clinical challenges that are associated with managing rare diseases such as hemophilia and SLE, optimally treating those patients are often tied to heavy economic burden that may often exceed $100,000 per year per patient. And while the total healthcare budget impact is minimal, managed care authorities are tasked with designing protocols that ensure the appropriate use of medications, deriving the highest value from the high cost therapies. While guidelines provide useful reference points in approaching rare conditions, they do not necessarily define the process of identifying the right patient and channeling them towards the right clinical care strategy, while minimizing waste and managing disparities in expectations.
Semaglutide Linked to Cardiovascular Gains, but Also Higher Health Spending
August 8th 2025A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and cholesterol, but also a $80 monthly rise in health care spending outside of drug costs.
Read More
